12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-121: Phase II data

Merrimack disclosed on a conference call to discuss its 2Q13 earnings that it will stop enrollment in Group B of a single-arm, open-label, international Phase II trial after a pre-specified interim analysis by a DSMB showed that MM-121 plus Tarceva erlotinib missed undisclosed criteria for continuing enrollment and would not meet the primary endpoint of improving PFS. Group B enrolled 43 of the planned 70 NSCLC patients with a known EGFR-activating mutation who have received no prior EGFR therapy in the metastatic setting. Data from the 43...

Read the full 434 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >